Troax Group AB: Troax Group acquires Stommpy SpA

CET Troax Group through its subsidiary Troax AB has entered into an agreement to acquire all outstanding shares of Italian based Stommpy SpA, including its Austrian ...

EnWave Corporation: EnWave Reports 2025 Fourth Quarter and Annual 2025 Consolidated Financial Results

EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", or the "Company") today reported the Company's consolidated interim financial results ...

Quipt Home Medical Corp.: Quipt Home Medical Enters Into Definitive Agreement for Its Acquisition by Affiliates of Kingswood Capital Management and Forager Capital Management

Quipt shareholders to receive US$3.65 per share in cashTransaction provides immediate liquidity and certainty of value to shareholdersThe per share purchase price represents a 162% premium to Quipt's ...

Oryzon Genomics, S.A.: ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting

All resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage ...

FibroGen, Inc.: Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan ...

Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel ...

Abpro Corporation: Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers

P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro's ...

Wesco International: Wesco Partners With Liberty Latin America to Provide Relief to Jamaican Communities Affected by Hurricane Melissa

PITTSBURGH, PA / ACCESS Newswire / December 15, 2025 / Wesco International (NYSE:WCC), a leading provider of business-to-business distribution, logistics services and supply chain solutions, in a join ...

Partners Group: Partners Group's announcement of AuM as of 31 December 2025

Annual Results Partners Group's announcement of AuM as of 31 December 2025 15.12.2025 / 15:00 CET/CEST Wednesday, 14 January 2026 6:15pm ...

Flagship Communities Real Estate Investment Trust Announces December 2025 Cash Distribution

Not for distribution to U.S. newswire services or dissemination in the United States TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Flagship Communities Real Estate Investment Trust ("Flagship" or the "RE ...

Vanda Pharmaceuticals Inc.: Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the submission of a Biologics License Application (BLA) ...

Capstone Holding Corp.: Capstone's 2026 Outlook Reaffirms $100M Run-Rate Target and Outlines Path to 10% EBITDA Margins

Record 2025 performance, rapid CSI integration, and improving demand conditions support profitable growth trajectory. NEW YORK CITY, NEW YORK / ACCESS Newswire / December 15, 2025 / Capstone Holding ...